1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

Journal article

Peer reviewed

K. Fizazi, M.J. Morris, N.D. Shore, K.N. Chi, M. Crosby, J.S. de Bono, K. Herrmann, G. Roubaud, J. Nagarajah, M.T. Fleming, …

Annals of oncology, Vol.35, pp.S964-S965

09/2024

Metrics

1 Record Views

Title: 1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Creators: K. Fizazi - Institut Gustave Roussy
M.J. Morris - Memorial Sloan Kettering Cancer Center
N.D. Shore - Carolina Urologic Research Center
K.N. Chi - BC Cancer Agency
M. Crosby - Health Awareness (United States)
J.S. de Bono - Royal Marsden Hospital
K. Herrmann - Essen University Hospital
G. Roubaud - Institut Bergonié
J. Nagarajah - Radboud University Nijmegen
M.T. Fleming - Virginia Oncology Associates
B. Lewis - Tulane University
L.T. Nordquist - Urology Cancer Center and GU Research Network
D.E. Castellano Gauna - Hospital Universitario 12 De Octubre
N. Carnahan - Tris Pharma (United States)
S. Ghebremariam - Novartis (United States)
M. Hertelendi - Novartis (Switzerland)
O. Sartor - Mayo Clinic
Publication Details: Annals of oncology, Vol.35, pp.S964-S965
Publisher: Elsevier Ltd
Identifiers: 991006262317102656
Academic Unit: Radiology
Language: English
Resource Type: Journal article